[1]陈纤纤,冯烈,周颖,等. 糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较[J]. 基础医学与临床,2023,43:1097-1103. [2]Rajasekaran A,Julian BA,Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease[J]. Am J Med Sci,2021,361: 176-194. [3]Hoste EA,Vaara ST,De Loor J,et al. Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort[J]. Crit Care,2020,24: 144-149. [4]Liao L,Zhao X,Zhou M,et al. sFlt-1: a double regulator in angiogenesis-related diseases[J]. Curr Pharm Des,2021,27: 4160-4170. [5]陈玲,吴小燕. IgA 肾病临床诊治指南(解读)[J]. 临床内科杂志,2015,1: 358-360. [6]马懿,曾蜀春. IgA肾病血清lncRNA lnc-TSI、lncRNA GAS5表达及与病情程度的相关性分析[J]. 中国社区医师,2022,1: 84-86. [7]田秀娟,黄晨. IgA肾病免疫炎症发病机制研究进展[J].中华肾脏病杂志,2020,36: 400-405. [8]韩艳,高原小雪,谢宇端. miR-29a、ET-1在IgA肾病患者血清中的表达及其临床意义[J]. 标记免疫分析与临床,2021,28: 1095-1099. [9]Yeo IJ,Lee CK,Han SB,et al. Roles of chitinase 3-like 1 in the development of cancer,neurodegenerative diseases,and inflammatory diseases[J]. Pharmacol Ther,2019,203: 107394-107399. [10]杜庆蕾,李俊叶,王峙.慢性肾小球肾炎患者血清CHI3L1、HSP60表达水平及其临床意义[J].中南医学科学杂志,2024,52:432-435. [11]Peperstraete H,Bové T,De Wolf D,et al. Potential of urine biomarkers CHI3K1,NGAL,TIMP-2,IGFBP7,and combinations as complementary diagnostic tools for acute kidney injury after pediatric cardiac surgery: a prospective cohort study[J]. Diagnostics (Basel),2023,3: 1047-1052. [12]Zhai Y,Liu Y,Qi Y,et al. The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy[J]. PLoS One,2020,15: e0234492. doi:10.1371/journal. pone.0234492.
|